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Objectives. The purposes of this study were to identify the
incidence of aortic smoke in an unselected cohort of patients and
to determine the utility of this measurement as a clinical marker
for future coronary events and long-term cardiac prognosis.
Background. Although spontaneous echo contrast detected
within the cardiac chambers has been associated with an in-
creased risk of thromboembolism, less is known about “smoke”
within the thoracic aorta and its relation to progression of
coronary artery disease.
Methods. We prospectively assessed 118 unselected, consecu-
tive male patients (mean age 67 years, range 29 to 86) who
underwent transesophageal echocardiography (TEE). The pres-
ence of aortic smoke was identified by swirling echodense shadows
distinct from high gain artifact. A positive result required confir-
mation by two of three independent observers.
Results. Aortic smoke without dissection was found in 25 of the
patients (21%). Indications for TEE, coronary risk factors, the
incidence of reduced left ventricular ejection fraction and mitral
insufficiency and known coronary artery disease severity collec-
tively did not differ significantly at baseline between the groups
with and without smoke. Follow-up averaged 20.4 months (range
18 to 24) and was 100% complete for mortality and 98% complete
for morbidity. The presence of aortic smoke was an independent
predictor of myocardial infarction (16.0% vs. 2.2%, p < 0.005) and
cardiac death (20.0% vs. 1.1%, p < 0.0001). These statistics
remained significant after covarying for age, ejection fraction
<50%, hypertension, diabetes, aortic dimension, the presence of
an atheromatous plaque and smoke in the left atrium.
Conclusions. Spontaneous echo contrast detected within the
thoracic aorta by transesophageal echocardiography is a common
and important clinical marker that is strongly associated with an
increased risk for future myocardial infarction and cardiac mor-
tality. Future studies will attempt to define the pathophysiology of
this relation and assess whether aggressive revascularization
strategies and antithrombotic therapy may aid in the reduction of
this risk.
(J Am Coll Cardiol 1997;30:71–75)
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Spontaneous echo contrast (SEC), or “smoke,” is defined as
the presence of swirling echodense shadows within the cardiac
chambers or vessels. It has been strongly associated with an
increased risk of thromboembolism. This relation has been
reported by several investigators who demonstrated an in-
creased incidence of left atrial SEC in patients with cerebral
thromboembolic events (1–6). Although the presence of SEC
is generally attributed to erythrocyte rouleau formation in the
setting of stagnant blood flow (7), several other hemorheologic
correlates of SEC have also been observed. These include the
presence of anticardiolipin antibody, an elevated erythrocyte
sedimentation rate and increased levels of plasma fibrinogen,
as well as plasma viscosity (8–10). Recently, visualization of
intracardiac SEC has been facilitated by the introduction of
transesophageal echocardiographic (TEE) transducers with
higher frequencies (typically 5.0 to 7.0 MHz) and enhanced
resolution (11,12). The unimpeded esophageal views provided
by TEE have also led to the observation of SEC within the
thoracic aorta (13). Aortic SEC is more commonly seen in
patients with severely reduced cardiac output, in the vicinity of
dilated or aneurysmal aortas or within the false lumen created
by aortic dissection. However, it has also been noted in the
absence of structural heart disease and in the presence of
normal aortic dimensions, and is associated with an increased
incidence of cerebroembolic events (13–15). The presence of
aortic SEC might also reflect a potential thrombogenic predis-
position for accelerated clinical progression of coronary artery
disease. We therefore prospectively assessed 118 unselected,
consecutive male patients who underwent TEE at our institu-
tion in an attempt to define the incidence of aortic SEC and to
examine its relation to future coronary events.
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Methods
Patient group. The study group consisted of 118 consecu-
tive male patients who were referred to the noninvasive
cardiology laboratory of the New York Veterans Affairs Med-
ical Center for TEE between July and November 1993. One
patient with dissection in the descending aorta was excluded
from the series. The remaining 117 patients constituted the
final cohort. All patients were male, with a mean (6SD) age of
67.4 6 10.5 years (range 29 to 86) at the time of the procedure.
The groups were divided into 25 patients (21.4%) with dem-
onstrated SEC in the thoracic aorta and 92 patients (78.6%)
with no evidence of aortic SEC.
Indications for referral for TEE did not differ between the
groups (Table 1) and included preoperative assessment before
cardiac surgery, a history of previous cryptogenic stroke or
transient ischemic attack, a possible cardiogenic source of
thromboembolism, a suspected thoracic aneurysm and assess-
ment of valvular disease, atrial septal defect, left atrial mem-
brane or pericardial disease.
Baseline characteristics. At the time of TEE, baseline data
on previous medical history and cardiac risk factors were
recorded for each patient. These characteristics (Table 2)
included age, hypertension, angina, diabetes, tobacco use,
previous myocardial infarction, presence and extent of coro-
nary artery disease, coronary artery bypass graft surgery,
congestive heart failure, peripheral embolic disease, atrial
fibrillation, left ventricular ejection fraction ,50% (from dig-
ital subtraction angiography or echocardiographic data), val-
vular heart disease, previous stroke or transient ischemic
attack, history of peripheral vascular disease (including symp-
toms of claudication, history of vascular bypass or amputative
surgery) and medications. Baseline characteristics differing
significantly between the groups included age, history of an-
gina, aspirin and beta-blocker therapy. The greater use of
beta-blockers in the “smoke” patients may explain the lower
incidence of angina in this group.
Echocardiography. Transesophageal echocardiographic
studies were performed with a Hewlett-Packard Sonos 1000
Echocardiography System. Patients were premedicated with
topical xylocaine anesthetic spray without intravenous premed-
ication. A 5.0-MHz biplane transducer (Hewlett-Packard) was
inserted orally and advanced to a depth of between 30 and
40 cm from the incisors. Images of the heart and great vessels
were obtained and recorded on videotape for subsequent
analysis. The descending thoracic aorta was visualized in the
horizontal plane. Images of the aorta were magnified and
compression was set to maximum. To consider whether SEC
was present, a distinctive pulsatile pattern of dynamic, swirling
echocardiographic shadows required visualization at this level
and required confirmation by at least two of three independent
observers.
Other data obtained from TEE (Table 2) included aortic
dimension, presence and severity of atheromatous plaque
(defined as mild 5 0 to #0.3 cm; moderate 5 .0.3 to ,0.5 cm;
severe 5 $0.5 cm), mobile atheroma, left and right atrial
smoke, patent foramen ovale, atrial septal defect, severe aortic
stenosis (#0.8 cm2), atrial septal aneurysm, left ventricular
aneurysm and aortic arch aneurysm. Factors that differed
significantly between the groups included presence of athero-
matous disease (with a predominance of moderate plaque) and
mobile atheroma.
Coronary anatomy. Data on coronary anatomy were ob-
tained by coronary arteriography, which was performed within
a mean of 36 days of TEE. This information was available for
nine patients with (36.0%) and 48 patients without (52.2%)
aortic SEC. A significant lesion was defined as $70% stenosis
of a major epicardial coronary artery. Additional information
obtained from cardiac catheterization (Table 2) included the
extent of coronary artery disease (one-, two- or three-vessel or
left main) and left ventricular ejection fraction. Results of
coronary arteriography did not demonstrate a significant dif-
ference in severity of known coronary artery disease between
the study groups.
Patient follow-up. Follow-up data was obtained by direct
telephone contact, hospital and computer records and the
Beneficiary Identification and Record Locator Subsystem (16),
which is a computerized data base that identifies veterans and
their dependents who receive compensation, pension, educa-
tion and other Veterans Affairs benefits. The accuracy rate is
95%. Follow-up was 100% complete for mortality and 98%
complete for morbidity.
All patients were followed for a mean (6SD) of 20.4 6 1.7
months (range 18 to 24). Primary end points (Table 3) included
death, myocardial infarction, coronary artery bypass graft
surgery (excluding index procedure for which TEE was per-
formed), percutaneous transluminal coronary angioplasty, ce-
rebrovascular accident or transient ischemic attack. Deaths
were further classified as cardiac or noncardiac. Acute myo-
cardial infarction was verified by hospital or physician records
Abbreviations and Acronyms
SEC 5 spontaneous echo contrast
TEE 5 transesophageal echocardiography
TIMI 5 Thrombolysis in Myocardial Infarction





CABG 8 (32.0%) 43 (47.8%)
CVA/TIA 8 (32.0%) 17 (18.4%)
R/O thrombosis/embolism 6 (24.0%) 12 (12.9%)
Thoracic aneurysm 1 (4.0%) 1 (1.1%)
Valvular disease 2 (8.0%) 16 (17.3%)
Atrial septal defect 0 (0.0%) 1 (1.1%)
Left atrial membrane 0 (0.0%) 1 (1.1%)
Effusion 0 (0.0%) 1 (1.1%)
*p 5 NS for all comparisons. Data presented are number (%) of patients.
CABG 5 coronary artery bypass graft surgery; CVA 5 cerebrovascular accident;
R/O 5 rule out; TIA 5 transient ischemic attack.
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Age (yr) 72.3 6 8.4 66.1 6 10.7 0.037
Hypertension 17 (68.0%) 53 (57.6%) NS
Angina 8 (32.0%) 51 (55.5%) 0.031
Diabetes 9 (36.0%) 24 (26.1%) NS
Tobacco use 1 (4.0%) 12 (13.0%) NS
MI 10 (40.0%) 29 (31.5%) NS
CABG 6 (24.0%) 11 (11.9%) NS
CHF 4 (16.0%) 21 (22.7%) NS
Peripheral embolic disease 1 (4.0%) 10 (10.8%) NS
AF 5 (20.0%) 11 (11.9%) NS
LVEF ,50% 8 (32.0%) 22 (23.0%) NS
Valvular heart disease
Mitral stenosis 1 (4.0%) 2 (2.1%) NS
Aortic stenosis 0 (0.0%) 8 (8.7%) NS
Mitral insufficiency 6 (24.0%) 15 (16.2%) NS
Aortic insufficiency 4 (16.0%) 10 (10.8%) NS
Mitral valve prolapse 0 (0.0%) 1 (1.1%) NS
TIA 5 (20.0%) 13 (14.2%) NS
CVA 7 (28.0%) 19 (20.6%) NS
PVD
Intermittent claudication 4 (16.0%) 10 (10.8%) NS
Femoropopliteal bypass 0 (0.0%) 5 (5.4%) NS
Aortofemoral bypass 0 (0.0%) 0 (0.0%) NS
Aortoiliac bypass 0 (0.0%) 1 (1.1%) NS
Abdominal aortic aneurysm 2 (8.0%) 1 (1.1%) NS
Thoracic aortic aneurysm 1 (4.0%) 1 (1.1%) NS
Carotid endarterectomy 2 (8.0%) 3 (3.3%) NS
Amputation 1 (4.0%) 1 (1.1%) NS
TEE data
Aortic dimension (cm) 2.7 6 0.35 2.6 6 0.32 NS
Atheromatous plaque 21 (84.0%) 62 (67.4%) 0.007
Absent 4 (16.0%) 30 (32.6%) NS
Mild (.0 to #0.3 cm) 13 (52.0%) 55 (59.8%) NS
Mod (0.3 to 0.5 cm) 6 (24.0%) 4 (4.3%) 0.002
Severe ($0.5 cm) 2 (8.0%) 3 (3.3%) NS
LA smoke 6 (24.0%) 10 (10.9%) NS
RA smoke 1 (4.0%) 0 (0.0%) NS
Mobile atheroma 4 (16.0%) 2 (2.2%) 0.005
PFO 3 (12.0%) 8 (8.7%) NS
ASD 0 (0.0%) 2 (2.2%) NS
Severe aortic stenosis (#0.8 cm2) 0 (0.0%) 4 (4.3%) NS
Atrial septal aneurysm 0 (0.0%) 2 (2.2%) NS
LV aneurysm 0 (0.0%) 2 (2.2%) NS
Aortic arch aneurysm 0 (0.0%) 1 (1.1%) NS
Cath data 9 (36.0%) 48 (52.2%) NS
1 VD 0 (0.0%) 3 (3.3%) NS
2 VD 1 (4.0%) 9 (9.7%) NS
3 VD 7 (28.0%) 32 (34.0%) NS
LMCA 4 (16.0%) 19 (20.6%) NS
Medications
Coumadin 1 (4.0%) 5 (5.4%) NS
Aspirin 14 (56.0%) 27 (29.3%) 0.013
Beta-blockers 15 (60.0%) 32 (34.9%) 0.023
ACE inhibitors 8 (32.0%) 20 (21.7%) NS
Ca21 channel blockers 9 (36.0%) 31 (33.7%) NS
Data presented are mean value 6 SD or number (%) of patients. ACE 5 angiotensin-converting enzyme; AF 5 atrial
fibrillation; CABG 5 coronary artery bypass graft surgery; Cath 5 cardiac catheterization; CHF 5 congestive heart failure;
CVA 5 cerebrovascular accident; LA 5 left atrial; LMCA 5 left main coronary artery disease; LVEF 5 left ventricular
ejection fraction; MI 5 myocardial infarction; Mod 5 moderate; PFO 5 patent foramen ovale; PVD 5 peripheral vascular
disease; RA 5 right atrial; TEE 5 transesophageal echocardiographic; TIA 5 transient ischemic attack; VD 5 vessel disease.
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using standard criteria of history, electrocardiogram and car-
diac enzyme levels.
Statistical analysis. Chi-square analysis of variables was
performed with p , 0.05 considered significant. The strength
of the association of aortic SEC with significant end points was
compared with several other variables of likely pathophysio-
logic importance using discriminant analysis with a stepwise
approach (Table 4). In this multivariate analysis, the predictive
value of aortic SEC was considered in combination with age,
hypertension, diabetes, left ventricular ejection fraction ,50%,
presence of aortic atheromatous disease, aortic dimension and
presence of left atrial SEC. Variables (p , 0.05) were entered
in a sequential (stepwise) manner into the model based on the
strength of their significance. Kaplan-Meier survival analysis
was performed for all-cause mortality and survival curves were
compared with the Scheffe´ F test.
Results
There was a significant increase in the incidence of both
myocardial infarction (16.0% vs. 2.2%, p , 0.005) and cardiac
death (20.0% vs. 1.1%, p , 0.0001) in the SEC group (Table
3). Other variables associated with myocardial infarction and
cardiac death after multivariate analysis were diabetes and left
ventricular ejection fraction ,50% (Table 4).
Of the five cardiac deaths in the SEC group, four were
secondary to coronary artery disease and one to congestive
heart failure. The one cardiac death in the non-SEC group was
secondary to coronary artery disease. Of the 22 noncardiac
deaths that occurred, six were due to sepsis, five to malignancy,
four to acquired immune deficiency syndrome, three to renal
failure and one each related to cerebrovascular disease, cir-
rhosis, peripheral vascular disease and trauma. Kaplan-Meier
survival analysis revealed a 64% versus 79% cumulative per-
cent survival in the SEC versus non-SEC groups, respectively,
during the follow-up period (p 5 0.04) (Fig. 1).
Discussion
Aortic SEC is a marker of cardiac events. Our data have
demonstrated that the presence of aortic SEC is associated
with a significant increase in coronary events and a poor
long-term cardiac prognosis. This may reflect an underlying
hematologic or systemic disorder predisposing to both aortic
SEC and coronary atherosclerosis. For example, an increase in
asymmetric high molecular weight plasma proteins (e.g., fibrin-
ogen) may favor the development of a red blood cell rouleau-
mediated “hyperviscosity-like” syndrome, which could result in
coronary thrombosis and also lead to the formation of aortic
SEC. Alternatively, aortic SEC may be a marker of more
generalized and severe atherosclerosis. Atherosclerotic plaque
in the aorta may lead to abnormal shear forces, which create
localized zones of stagnant flow and hypercoagulability, man-
ifested as aortic SEC.
The Thrombolysis in Myocardial Infarction trials (TIMI)
have established the association of “low” coronary blood flow
(TIMI flow grade #2), as seen angiographically, with a signif-
icantly poor outcome in patients after thrombolytic therapy
(17–20). Could aortic SEC, similarly associated with poor
outcomes, represent an echocardiographic correlate of this
angiographic phenomenon and represent a region in the
thoracic aorta with low flow velocities? The poor outcomes
Table 4. Results of Stepwise Discriminant Analysis
End Point
Independent Variable Overall Model
Variable F Value p Value Wilks’ Lambda p Value
MI
Step 1 Aortic smoke 8.13 ,0.01 0.934 0.0052
Step 2 Diabetes 6.13 ,0.05 0.903 0.0030
Cardiac death
Step 1 Aortic smoke 16.21 ,0.001 0.876 0.0001
Step 2 LVEF ,50% 14.49 ,0.01 0.797 0.0000
Abbreviations as in Table 2.







MI 4 (16.0%) 2 (2.2%) 0.005
CABG 0 (0.0%) 2 (2.2%) 0.457
PTCA 2 (8.0%) 1 (1.1%) 0.053
CVA/TIA 5 (20.2%) 13 (14.2%) 0.471
Total deaths 9 (36.0%) 19 (20.6%) 0.107
Cardiac deaths 5 (20.0%) 1 (1.1%) 0.0001
Data presented are number (%) of patients. PTCA 5 percutaneous trans-
luminal coronary angioplasty; other abbreviations as in Table 2.
Figure 1. Kaplan-Meier survival analysis of cumulative percent sur-
vival between the groups. The groups differed significantly (p 5 0.04).
Solid line 5 no aortic smoke group; dashed line 5 aortic smoke group.
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noted with aortic SEC could parallel the relation between
increased surface expression of the inducible fibrinogen recep-
tor on platelets (GPIIb/IIIa) and its ability to independently
predict thrombosis in stented coronary vessels (21).
Limitations and need for further corroborative studies.
Although the relation between aortic SEC and cardiac events
appears to exist when SEC is visualized within the descending
thoracic aorta, we did not evaluate a correlation between SEC
at this level with that occurring more proximally. Differences in
proximal, arch and descending aortic flow velocities were not
recorded or compared. This is an important limitation of our
study. Furthermore, measurement of cardiac output would
have allowed for an assessment of flow velocities with other
abnormal stroke volume states (e.g., diastolic dysfunction).
These might have contributed to the poor outcomes related to
aortic SEC. Larger randomized trials will be necessary to
define the pathophysiology of this relation and to assess
whether aggressive revascularization strategies or anticoagu-
lant or antiplatelet function therapy, or a combination of these,
may serve to reduce this risk.
The patients with aortic SEC in this study were older, had
a higher incidence of atheromatous plaque and were more
likely to be treated with beta-blockers and aspirin than control
patients without aortic SEC. This suggests that aortic SEC may
be an easily identifiable marker for multiple risk factors rather
than a risk factor on its own. A limitation of our study is that
we did not include use of beta-blockers and aspirin in our
multivariate analysis. Use of these medications may imply a
sicker patient cohort; however, these drugs have a cardiopro-
tective effect, and the fact that a higher cardiac mortality was
observed in the “smoke” group despite treatment suggests that
aortic SEC does have important prognostic significance. Our
multivariate analysis (which included risk factors for coronary
events and cardiac death) suggests that aortic SEC is, in fact,
an independent factor associated with coronary events; how-
ever, larger studies with better matched groups will be required
to validate this hypothesis. Similarly, larger studies will be
needed to validate the hypothesis that aortic SEC is associated
in a causal fashion with the development of transient ischemic
attack and stroke, which surprisingly were not more frequent in
this cohort of patients with aortic SEC. Such studies should be
performed to determine whether patients with aortic SEC are
a heterogeneous group of high risk patients that would benefit
from aggressive risk factor modification, or whether aortic SEC
represents a specific disorder amenable to pharmacologic
treatment.
We acknowledge Joseph Bosco and Anthony Moschetto, MD for their technical
assistance.
References
1. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage
blood flow velocity, spontaneous echocardiographic contrast and thrombo-
embolic risk in vivo. J Am Coll Cardiol 1994;23:961–9.
2. Leung DYC, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic
implications of left atrial spontaneous echo contrast in nonvalvular atrial
fibrillation. J Am Coll Cardiol 1994;24:755–62.
3. Albers GW, Comess KA, DeRook FA, et al. Transesophageal echocardio-
graphic findings in stroke subtypes. Stroke 1994;25:23–8.
4. Hwang JJ, Kuan P, Chen JJ, et al. Significance of left atrial spontaneous echo
contrast in rheumatic mitral valve disease as a predictor of systemic arterial
embolization: a transesophageal echocardiographic study. Am Heart J
1994;127:880–5.
5. Black IW, Chesterman CN, Hopkins AP, Lee LCL, Chong BH, Walsh WF.
Hematologic correlates of left atrial spontaneous echo contrast and throm-
boembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993;21:
451–7.
6. Black IW, Hopkins AP, Lincoln LCL, Walsh WF. Left atrial spontaneous
echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol
1991;18:398–404.
7. Wang XF, Liu L, Cheng TO, Li ZA, Deng YB, Wang JE. The relationship
between intracardiovascular smoke-like echo and erythrocyte rouleaux for-
mation. Am Heart J 1992;124:961–5.
8. Fatkin D, Herbert E, Feneley MP. Hematologic correlates of spontaneous
echo contrast in patients with atrial fibrillation and implications for throm-
boembolic risk. Am J Cardiol 1994;73:672–6.
9. Siostrzonek P, Koppensteiner R, Go¨ssinger H, et al. Hemodynamic and
hemorheologic determinants of left atrial spontaneous echo contrast and
thrombus formation in patients with idiopathic dilated cardiomyopathy. Am
Heart J 1993;125:430–4.
10. Merino A, Hauptman P, Badimon L, et al. Echocardiographic “smoke” is
produced by an interaction of erythrocytes and plasma proteins modulated
by shear forces. J Am Coll Cardiol 1992;20:1661–8.
11. Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesoph-
ageal echocardiography in detecting cardiac source of embolism in patients
with cerebral ischemia of uncertain etiology. J Am Coll Cardiol 1991;17:66–
72.
12. DeRook FA, Comess KA, Albers GW, Popp RL. Transesophageal echocar-
diography in the evaluation of stroke. Ann Intern Med 1992;117:922–32.
13. deFilippi CR, Lacker M, Grayburn PA, Brickner ME. Spontaneous echo
contrast in the descending aorta detected by transesophageal echocardiog-
raphy. Am J Cardiol 1994;74:410–1.
14. Panidis IP, Kotler MN, Mintz GS, Ross J. Intracavitary echoes in the aortic
arch in type III aortic dissection. Am J Cardiol 1984;54:1159–60.
15. Finkelhor RS, Lamont WE, Ramanavarapu SK, Bahler RC. Spontaneous
echocardiographic contrast in the thoracic aorta: factors associated with its
occurrence and its association with embolic events. Am Heart J 1995;130:
1254–8.
16. Kang HK. Resources for epidemiologic research in Vietnam era veteran
populations within the Department of Veterans Affairs. In: Page WF, editor.
Epidemiology in Military and Veteran Populations. Washington, DC: Na-
tional Academy Press, 1991:97–103.
17. Lincoff AM, Topol EJ, Califf RM, et al., for the Thrombolysis and Angio-
plasty in Myocardial Infarction Study Group. Significance of a coronary
artery with thrombolysis in myocardial infarction grade 2 flow “patency”
(outcome in the thrombolysis and angioplasty in myocardial infarction
trials). Am J Cardiol 1995;75:871–6.
18. Gibson CM, Cannon CP, Piana RN, et al. Angiographic predictors of
reocclusion after thrombolysis: results from the Thrombolysis in Myocardial
Infarction (TIMI) 4 trial. J Am Coll Cardiol 1995;25:582–9.
19. Anderson JL, Karagounis LA, Becker LC, Sorenson SG, Menlove RL. TIMI
perfusion grade 3 but not grade 2 results in improved outcome after
thrombolysis for myocardial infarction: ventriculographic, enzymatic, and
electrocardiographic evidence from the TEAM-3 study. Circulation 1993;87:
1829–39.
20. Karagounis L, Sorenson SG, Menlove RL, Moreno F, Anderson JL. Does
thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a
mostly patent artery or a mostly occluded artery? Enzymatic and electrocar-
diographic evidence from the second multicenter Thrombolytic trial of
Eminase in Acute Myocardial Infarction (TEAM-2) study. J Am Coll
Cardiol 1992;19:1–10.
21. Neumann FJ, Gawaz M, Ott I, May A, Mo¨ssmer G, Scho¨mig A. Prospective
evaluation of hemostatic predictors of subacute stent thrombosis after
coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996;27:15–21.
75JACC Vol. 30, No. 1 STEINBERG ET AL.
July 1997:71–75 AORTIC SMOKE AND CORONARY DISEASE PROGRESSION
